Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Leading Change in Academic Pharmacy: Report of the 2018-2019 AACP Academic Affairs Committee.

Gregory DF, Boje KM, Carter RA, Daugherty KK, Hagemeier NE, Munger MA, Umland EM, Wagner JL.

Am J Pharm Educ. 2019 Dec;83(10):7661. doi: 10.5688/ajpe7661.

2.

Modeling Doctor of Pharmacy Students' Stress, Satisfaction, and Professionalism Over Time.

Tak C, Henchey C, Feehan M, Munger MA.

Am J Pharm Educ. 2019 Nov;83(9):7432. doi: 10.5688/ajpe7432.

3.

A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism.

Allahwerdy F, Pan S, Feehan M, Jones AE, Munger MA, Witt DM.

Pharm Pract (Granada). 2019 Jul-Sep;17(3):1539. doi: 10.18549/PharmPract.2019.3.1539. Epub 2019 Aug 22.

4.

Understanding Factors Associated with Quality of Life in Patients with Venous Thromboembolism.

Erickson RM, Feehan M, Munger MA, Tak C, Witt DM.

Thromb Haemost. 2019 Nov;119(11):1869-1876. doi: 10.1055/s-0039-1696717. Epub 2019 Oct 6.

PMID:
31587248
5.

Associations between anticoagulant treatment pathways and self-reported harms in patients recently diagnosed with venous thromboembolism.

Pan S, Allahwerdy F, Kim K, Feehan M, Jones AE, Munger MA, Witt DM.

Thromb Res. 2019 Oct;182:95-100. doi: 10.1016/j.thromres.2019.08.006. Epub 2019 Aug 13.

PMID:
31473404
6.

Patient Satisfaction With Venous Thromboembolism Treatment.

Webb D, Kim K, Tak CR, Witt DM, Feehan M, Munger MA.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619864663. doi: 10.1177/1076029619864663.

7.

Understanding patients' care barriers in the treatment of venous thromboembolism.

Pulleyn T, Kim K, Witt DM, Feehan M, Munger MA.

J Thromb Thrombolysis. 2019 Jul;48(1):35-41. doi: 10.1007/s11239-019-01880-3.

PMID:
31102162
8.

Payers' Perspectives on Pharmacist-Directed Care in a Community Pharmacy Setting.

Merrill BS, Tak CR, Feehan M, Munger MA.

Ann Pharmacother. 2019 Sep;53(9):916-921. doi: 10.1177/1060028019839440. Epub 2019 Mar 21.

PMID:
30895798
9.

Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.

Bress AP, Dodson JA, King JB, Sauer BC, Reese T, Crook J, Radwanski P, Knippenberg K, Greene T, Nelson RE, Munger MA, Weintraub WS, LaFleur J.

Am J Cardiol. 2018 Dec 1;122(11):1809-1816. doi: 10.1016/j.amjcard.2018.08.027. Epub 2018 Sep 8.

PMID:
30292334
10.

Integrating Family Medicine and Community Pharmacy to Improve Patient Access to Quality Primary Care and Enhance Health Outcomes.

Munger MA, Sundwall DN, Feehan M.

Am J Pharm Educ. 2018 May;82(4):6572. doi: 10.5688/ajpe6572. Review. No abstract available.

11.

Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: A cross-sectional structural equation model.

Feehan M, Walsh M, Van Duker H, Godin J, Munger MA, Fleming R, Johnson SA, Morrison MA, DeAngelis MM, Witt DM.

Thromb Res. 2018 Dec;172:181-187. doi: 10.1016/j.thromres.2018.05.025. Epub 2018 May 23.

PMID:
29843918
12.

Pharmacist's Demand for Optimal Primary Care Service Delivery in a Community Pharmacy: The OPTiPharm Study.

Munger MA, Walsh M, Godin J, Feehan M.

Ann Pharmacother. 2017 Dec;51(12):1069-1076. doi: 10.1177/1060028017722795. Epub 2017 Jul 24.

PMID:
28737045
13.

Factors predicting self-reported medication low adherence in a large sample of adults in the US general population: a cross-sectional study.

Feehan M, Morrison MA, Tak C, Morisky DE, DeAngelis MM, Munger MA.

BMJ Open. 2017 Jun 23;7(6):e014435. doi: 10.1136/bmjopen-2016-014435. Erratum in: BMJ Open. 2017 Sep 1;7(8):e014435corr1.

14.

Patient preferences for healthcare delivery through community pharmacy settings in the USA: A discrete choice study.

Feehan M, Walsh M, Godin J, Sundwall D, Munger MA.

J Clin Pharm Ther. 2017 Dec;42(6):738-749. doi: 10.1111/jcpt.12574. Epub 2017 Jun 18.

PMID:
28627110
15.

Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.

King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP.

Pharmacotherapy. 2017 Jun;37(6):662-672. doi: 10.1002/phar.1939.

PMID:
28475215
16.

Adherence to Glaucoma Medications Over 12 Months in Two US Community Pharmacy Chains.

Feehan M, Munger MA, Cooper DK, Hess KT, Durante R, Jones GJ, Montuoro J, Morrison MA, Clegg D, Crandall AS, DeAngelis MM.

J Clin Med. 2016 Sep 7;5(9). pii: E79. doi: 10.3390/jcm5090079.

17.

Qualitative interviews regarding pharmacist prescribing in the community setting.

Feehan M, Durante R, Ruble J, Munger MA.

Am J Health Syst Pharm. 2016 Sep 15;73(18):1456-61. doi: 10.2146/ajhp150691.

PMID:
27605325
18.

Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.

King JB, Bress AP, Reese AD, Munger MA.

Pharmacotherapy. 2015 Sep;35(9):823-37. doi: 10.1002/phar.1629. Review.

PMID:
26406774
19.

Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain.

Feehan M, Ranker L, Durante R, Cooper DK, Jones GJ, Young DC, Munger MA.

J Clin Pharm Ther. 2015 Oct;40(5):590-593. doi: 10.1111/jcpt.12316. Epub 2015 Aug 20.

PMID:
26291693
20.

Assessing orally bioavailable commercial silver nanoparticle product on human cytochrome P450 enzyme activity.

Munger MA, Hadlock G, Stoddard G, Slawson MH, Wilkins DG, Cox N, Rollins D.

Nanotoxicology. 2015 May;9(4):474-81. doi: 10.3109/17435390.2014.948092. Epub 2014 Aug 19.

PMID:
25137296
21.

National evaluation of prescriber drug dispensing.

Munger MA, Ruble JH, Nelson SD, Ranker L, Petty RC, Silverstein S, Barton E, Feehan M.

Pharmacotherapy. 2014 Oct;34(10):1012-21. doi: 10.1002/phar.1461. Epub 2014 Jul 23.

PMID:
25053590
22.

Primary care pharmacists: provision of clinical-decision services in healthcare.

Munger MA.

Am J Pharm Educ. 2014 Mar 12;78(2):43. doi: 10.5688/ajpe78243. No abstract available.

23.

Community pharmacists' occupational satisfaction and stress: a profession in jeopardy? Response to Rodis and Ulbrich.

Munger MA, Feehan M.

J Am Pharm Assoc (2003). 2014 Jan-Feb;54(1):7. doi: 10.1331/JAPhA.2014.13183. No abstract available.

PMID:
24407738
24.

Icosapent ethyl for treatment of elevated triglyceride levels.

Nelson SD, Munger MA.

Ann Pharmacother. 2013 Nov;47(11):1517-23. doi: 10.1177/1060028013504079. Epub 2013 Nov 5. Review.

PMID:
24259598
25.

In vivo human time-exposure study of orally dosed commercial silver nanoparticles.

Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE.

Nanomedicine. 2014 Jan;10(1):1-9. doi: 10.1016/j.nano.2013.06.010. Epub 2013 Jun 28.

26.

Community pharmacists' occupational satisfaction and stress: a profession in jeopardy?

Munger MA, Gordon E, Hartman J, Vincent K, Feehan M.

J Am Pharm Assoc (2003). 2013 May-Jun;53(3):282-96. doi: 10.1331/JAPhA.2013.12158.

PMID:
23699677
27.

Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation.

Smock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger DW, Munger MA.

Nanotoxicology. 2014 May;8(3):328-33. doi: 10.3109/17435390.2013.788749. Epub 2013 May 2.

PMID:
23517080
28.

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons.

J Am Coll Cardiol. 2012 Dec 18;60(24):e44-e164. doi: 10.1016/j.jacc.2012.07.013. Epub 2012 Nov 19. No abstract available.

29.

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV.

J Am Coll Cardiol. 2012 Dec 18;60(24):2564-603. doi: 10.1016/j.jacc.2012.07.012. Epub 2012 Nov 19. No abstract available.

30.

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV, Anderson JL; American College of Cardiology Foundation/American Heart Association Task Force.

Circulation. 2012 Dec 18;126(25):e354-471. doi: 10.1161/CIR.0b013e318277d6a0. Epub 2012 Nov 19. No abstract available. Erratum in: Circulation. 2014 Apr 22;129(16):e463.

PMID:
23166211
31.

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV; American College of Cardiology Foundation.

Circulation. 2012 Dec 18;126(25):3097-137. doi: 10.1161/CIR.0b013e3182776f83. Epub 2012 Nov 19. No abstract available. Erratum in: Circulation. 2014 Apr 22;129(16):e462.

PMID:
23166210
33.

Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitus.

Munger MA.

Drugs Aging. 2010 Nov 1;27(11):871-83. doi: 10.2165/11538650-000000000-00000. Review.

PMID:
20964461
34.

Nanosilver particle effects on drug metabolism in vitro.

Lamb JG, Hathaway LB, Munger MA, Raucy JL, Franklin MR.

Drug Metab Dispos. 2010 Dec;38(12):2246-51. doi: 10.1124/dmd.110.035238. Epub 2010 Sep 22.

PMID:
20861156
35.

Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record database.

Brixner DI, McAdam-Marx C, Ye X, Lau H, Munger MA.

Curr Med Res Opin. 2010 Aug;26(8):1881-91. doi: 10.1185/03007995.2010.489785.

PMID:
20528221
36.

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.

Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN.

J Hum Hypertens. 2010 Sep;24(9):600-8. doi: 10.1038/jhh.2009.107. Epub 2009 Dec 24.

PMID:
20033075
37.

High-impact articles related to the management of heart failure: 2008 update.

Jackevicius CA, Page RL 2nd, Chow S, Dunn SP, Lee CR, Ng TM, Rodgers JE, Vardeny O, Wiggins BS, Munger MA.

Pharmacotherapy. 2009 Jan;29(1):82-120. doi: 10.1592/phco.29.1.82.

PMID:
19113799
38.

Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.

Van Tassell BW, Radwanski P, Movsesian M, Munger MA.

Pharmacotherapy. 2008 Dec;28(12):1523-30. doi: 10.1592/phco.28.12.1523. Review.

PMID:
19025433
39.

Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine.

Munger MA, Stoddard GJ, Wenner AR, Bachman JW, Jurige JH, Poe L, Baker DL.

Mayo Clin Proc. 2008 Aug;83(8):890-6. doi: 10.4065/83.8.890.

PMID:
18674473
40.

Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.

Van Tassell BW, Rondina MT, Huggins F, Gilbert EM, Munger MA.

Am Heart J. 2008 Aug;156(2):315-21. doi: 10.1016/j.ahj.2008.04.004. Epub 2008 Jun 20.

41.

Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study.

Munger MA, Gardner SF, Ateshkadi A, Rabetoy GM, Barri YM, Stoddard GJ, Cheung AK; MEDIC Study Investigators.

Pharmacotherapy. 2008 Jul;28(7):834-42. doi: 10.1592/phco.28.7.834.

PMID:
18576898
42.

Medication nonadherence: an unrecognized cardiovascular risk factor.

Munger MA, Van Tassell BW, LaFleur J.

MedGenMed. 2007 Sep 19;9(3):58. Review.

43.

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.

Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL.

J Clin Hypertens (Greenwich). 2007 Oct;9(10):742-50.

44.

Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.

Munger MA, Ng TM, Van Tassell BW.

Pharmacotherapy. 2007 May;27(5):619-25. Review.

PMID:
17461695
45.

Aliskiren for renin inhibition: a new class of antihypertensives.

Van Tassell BW, Munger MA.

Ann Pharmacother. 2007 Mar;41(3):456-64. Epub 2007 Mar 6. Review.

PMID:
17341529
46.

New agents for managing hyponatremia in hospitalized patients.

Munger MA.

Am J Health Syst Pharm. 2007 Feb 1;64(3):253-65. Review.

PMID:
17244874
47.
48.

High-impact articles related to the pharmacotherapeutic management of systolic heart failure.

Ng TM, Carter O, Guillory GS, Howard PA, Lee CR, Rodgers JE, Uber PA, Wiggins BS, Munger MA, Patterson JH.

Pharmacotherapy. 2004 Nov;24(11):1594-633.

PMID:
15537564
49.

Atherothrombosis: epidemiology, pathophysiology, and prevention.

Munger MA, Hawkins DW.

J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2 Suppl 1):S5-12; quiz S12-3. Review.

PMID:
15095931
50.

Epidemiology and practice patterns of acute decompensated heart failure.

Munger MA, Carter O.

Am J Health Syst Pharm. 2003 Aug 15;60 Suppl 4:S3-6.

PMID:
12966900

Supplemental Content

Loading ...
Support Center